MedTrace Logo

P.Vivax Treatment Trial

NCT02802813 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2022-03-02

No results posted yet for this study

Summary

This study aims to determine whether a 14 day course of 0.5 mg/kg/day primaquine can eliminate subclinical P. vivax infections detected by high volume ultra-sensitive PCR (uPCR).

Conditions

  • Plasmodium Vivax

Interventions

DRUG

Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)

DRUG

Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo

Sponsors & Collaborators

  • Mahidol Oxford Tropical Medicine Research Unit

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Mayfong Mayxay, MD · Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-14
Primary Completion
2018-06-15
Completion
2018-06-15

Countries

  • Laos

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02802813 on ClinicalTrials.gov